Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Telomir Pharmaceuticals, Inc. (TELO : NSDQ)

• Company Description    Telomir Pharmaceuticals Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Telomir Pharmaceuticals Inc. is based in BALTIMORE. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $1.29 Daily Weekly Monthly 20 Day Moving Average: 234,391 shares Shares Outstanding: 68.78 (millions) Market Capitalization: $88.72 (millions) Beta: -0.21 52 Week High: $3.10 52 Week Low: $1.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.52% -11.09% 12 Week -1.53% -8.97% Year To Date -3.01% -10.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 SE 2ND STREET SUITE 2000 -1009 - MIAMI,FL 33131 USA ph: 786-396-6723 fax: - info@telomirpharma.com http://www.telomirpharma.com

• General Corporate Information    Officers Erez Aminov - Chief Executive Officer and Chairman Alan Weichselbaum - Chief Financial Officer Ned MacPherson - Director Matthew Pratt Whalen - Director Matthew P. Del Giudice - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 87975F104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 68.78 Most Recent Split Date: (:1) Beta: -0.21 Market Capitalization: $88.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 17.88 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 57.14% vs. Previous Quarter: 50.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -201.23 12/31/25 - -315.26 09/30/25 - -566.61 ROA 03/31/26 - -172.71 12/31/25 - -259.29 09/30/25 - -447.89 Current Ratio 03/31/26 - 7.00 12/31/25 - 5.14 09/30/25 - 17.50 Quick Ratio 03/31/26 - 7.00 12/31/25 - 5.14 09/30/25 - 17.50 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.07 12/31/25 - 0.17 09/30/25 - 0.22 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©